tazemetostat (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Epithelial Sarcoma

EZH2 inhibitor pending FDA approval

Orphan Designations

Follicular lymphoma (FL)

Malignant rhabdoid tumors (MRTs)

Mesothelioma

Soft tissue sarcoma

Orphan Sponsor

  • Epizyme, Inc; 400 Technology Square,4th Floor Cambridge, Massachusetts 02139
Next:

Pharmacology

Mechanism of Action

Enhancer of zeste homolog 2 (EZH2) inhibitor

Misregulated EZH2 enzyme activity results in poorly regulated genes that control cell proliferation

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.